

PUBLICATIONS AND COMMUNICATIONS

Main publications from Pr M Mohty, Medical Advisor

1: Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kahl P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. *J Hematol Oncol.* 2017 Jun 24;10(1):130

2: Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, Cornelissen JJ, Chevallier P, Sanz G, Petersen E, Savani BN, Gluckman E, Nagler A. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. *J Hematol Oncol.* 2017 Jun 21;10(1):128.

3: Eder S, Canaani J, Beohou E, Labopin M, Sanz MA, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socié G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A; Acute Leukemia Working Party. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Hematol.* 2017 Jun 14.

4: Illiaquer M, Imbert-Marcille BM, Guillaume T, Planche L, Rimbert M, Bressollette-Bodin C, Le Bourgeois A, Peterlin P, Garnier A, Le Houerou C, Moreau P, Mohty M, Chevallier P. Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults. *J Clin Virol.* 2017 May 31;93:30-36.

5: Chabannon C, Bijou F, Grouin JM, Drillat P, Milpied N, Mohty M. The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest. *Bone Marrow Transplant.* 2017 Jun 5.]

6: Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y, Tischer J, Santarone S, Giebel S, Mohty M, Nagler A. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. *J Hematol Oncol.* 2017 May 30;10(1):113.

7: Mohty M, Drillat P, Grouin JM, Bijou F, Milpied N, Chabannon C. Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function. *Bone Marrow Transplant.* 2017 May 22.

8: Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, Nagler A, Bacigalupo A. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. *Bone Marrow Transplant.* 2017 May 15.

9: Canaani J, Savani BN, Labopin M, Michallet M, Craddock C, Socié G, Volin L, Maertens JA, Crawley C, Blaise D, Ljungman PT, Cornelissen J, Russell N, Baron F, Gorin N, Esteve J, Ciceri F, Schmid C, Giebel S, Mohty M, Nagler A. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. *Am J Hematol.* 2017 Apr 25.

10: Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. *Cancer.* 2017 Apr 7

11: Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. *Am J Hematol.* 2017 Jul;92(7):653-659.

12: Lestang E, Peterlin P, Le Bris Y, Dubrulle V, Delaunay J, Godon C, Theisen O, Blin N, Mahe B, Gastinne T, Garnier A, Touzeau C, Voldoire M, Bene MC, Le Gouill S, Milpied N, Mohty M, Moreau P, Guillaume T, Chevallier P. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? *Eur J Haematol.* 2017 Jul;99(1):60-69.

13: Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C, Mohty M. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. *Bone Marrow Transplant.* 2017 Mar 27.

14: Sengsayadeth S, Malard F, Savani BN, Garderet L, Mohty M. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. *Blood Cancer J.* 2017 Mar 24;7(3):e545.

15: Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foá R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer.* 2017 Mar 22.

16: Hirsch P, Tang R, Abermil N, Flandrin P, Moatti H, Favale F, Suner L, Lorre F, Marzac C, Fava F, Mamez AC, Lapusan S, Isnard F, Mohty M, Legrand O, Douay L, Bilhou-Nabera C, Delhommeau F. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. *Haematologica.* 2017 Mar 16. pii: haematol.2016.159681.

17: Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. *Bone Marrow Transplant.* 2017 Jun;52(6):811-817.

- 18: Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Tischler J, Koc Y, Bruno B, Gülbas Z, Blaise D, Maertens J, Ehninger G, Mohty M, Nagler A. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. *Haematologica*. 2017 Jun;102(6):1066-1074.
- 19: Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. *Cancer*. 2017 Jun 1;123(11):1965-1970.
- 20: Shouval R, Bonifazi F, Fein J, Boschini C, Oldani E, Labopin M, Raimondi R, Sacchi N, Dabash O, Unger R, Mohty M, Rambaldi A, Nagler A. Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. *Am J Hematol*. 2017 May;92(5):429-434.
- 21: Jarry A, Malard F, Bou-Hanna C, Meurette G, Mohty M, Mosnier JF, Laboisie CL, Bossard C. Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa. *Cell Mol Gastroenterol Hepatol*. 2016 Sep 20;3(1):72-81.
- 22: Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. *Lancet Infect Dis*. 2017 May;17(5):510-519.
- 23: Le Bris Y, Guillaume T, Ménard A, Illiaquer M, Martin J, Malard S, Duquesne A, Peterlin P, Debord C, Robillard N, Eveillard M, Wuillème S, Delaunay J, Mohty M, Garnier A, Moreau P, Béné MC, Chevallier P. Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults. *Bone Marrow Transplant*. 2017 Jun;52(6):854-858.
- 24: Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. *J Hematol Oncol*. 2017 Jan 24;10(1):31
- 25: Roux C, Tifratene K, Socié G, Galambrun C, Bertrand Y, Rialland F, Jubert C, Pochon C, Paillard C, Sirvent A, Nelken B, Vannier JP, Freycon C, Beguin Y, Raus N, Yakoub-Agha I, Mohty M, Dalle JH, Michel G, Pradier C, Peffault de Latour R, Rohrlich PS. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). *Bone Marrow Transplant*. 2017 May;52(5):678-682.
- 26: Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrzcz-Krzemien S, Santarone S,

Huang H, Beelen D, Gorin NC, Craddock C, Gulbas Z, Bacigalupo A, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. *J Hematol Oncol*. 2017 Jan 19;10(1):24.

27: Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, Socié G, Gedde-Dhal T, Schaap N, Cornelissen JJ, Vigouroux S, Sanz J, Michaux L, Esteve J, Mohty M, Nagler A. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). *J Hematol Oncol*. 2017 Jan 18;10(1):20.

28: Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, Michallet M, Ruggeri A, Contentin N, Ribera JM, Stadler M, Sierra J, von dem Borne PA, Bloor A, Socié G, Nagler A, Mohty M. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2017 Apr;52(4):592-599.

29: Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. *Am J Hematol*. 2017 Apr;92(4):344-350

30: Wallhult E, Kenyon M, Liptrott S, Mank A, Ní Chonghaile M, Babic A, Bijkerk J, Bompont C, Corbacioglu S, de Weijer R, Fink C, Markt S, Soni V, Sprenger S, Arjona ET, Mohty M. Management of veno-occlusive disease: the multidisciplinary approach to care. *Eur J Haematol*. 2017 Apr;98(4):322-329.

31: Meissner J, Finel H, Dietrich S, Boumendil A, Kanfer E, Laboure G, Abecasis M, Cornelissen J, Delage J, Finke J, Hess U, Ludwig H, Mohty M, Pabst T, Pioltelli P, Robinson S, Samaras P, Montoto S, Dreger P. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience. *Bone Marrow Transplant*. 2017 Apr;52(4):650-652

32: Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2017 Feb;102(2):224-234.

33: Polomeni A, Bompont C, Gomez A, Brissot E, Ruggeri A, Belhocine R, Mohty M. Current practices for screening, consent and care of related donors in France: Haematopoietic stem cell transplantation coordinator nurses' perceptions. *Eur J Cancer Care (Engl)*. 2016 Dec 6. doi: 10.1111/ecc.12612. [Epub ahead of print] PMID: 27922202.

34: Gorin NC, Labopin M, Czerw T, Pabst T, Blaise D, Dumas PY, Nemet D, Arcese W,

Trisolini SM, Wu D, Huynh A, Zuckerman T, Meijer E, Cagirgan S, Cornelissen J, Houhou M, Polge E, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). *Cancer*. 2017 Mar 1;123(5):824-831

35: Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte RF. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. *Bone Marrow Transplant*. 2017 Mar;52(3):357-362

36: Malard F, Harousseau JL, Mohty M. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. *Cancer Treat Rev*. 2017 Jan;52:41-47.

37: Ringdén O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, Ganser A, Michallet M, Kanz L, Schwerdtfeger R, Nagler A, Mohty M; Acute Leukaemia Working Party of the EBMT. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. *Br J Haematol*. 2017 Feb;176(3):431-439.

38: Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. *J Hematol Oncol*. 2016 Nov 8;9(1):118.

39: Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2017 Feb;52(2):191-196.

40: Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani BN, Mohty M, Nagler A. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2017 Feb;23(2):278-284.

41: Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, Gorin NC, Giebel S, Mohty M, Savani BN, Nagler A. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. *Bone Marrow Transplant*. 2016 Nov;51(11):1431-1438.

42: Garderet L, Beohou E, Caillot D, Stoppa AM, Touzeau C, Chretien ML, Karlin L, Moreau P, Fontan J, Blaise D, Polge E, Gueye MS, Ikhlef S, Marjanovic Z, Labopin

- M, Mohty M. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. *Haematologica*. 2016 Nov;101(11):1390-1397
- 43: Antar A, Otrrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A. Inhibition of FLT3 in AML: a focus on sorafenib. *Bone Marrow Transplant*. 2017 Mar;52(3):344-351.
- 44: Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, Santarone S, Gülbas Z, Blaise D, Messina G, Ghavamzadeh A, Malard F, Bruno B, Diez-Martin JL, Koc Y, Ciceri F, Mohty M, Nagler A. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. *Haematologica*. 2017 Feb;102(2):401-410
- 45: Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):140-146.
- 46: Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. *Cancer Med*. 2016 Nov;5(11):3068-3076.
- 47: Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2016 Dec;22(12):2117-2125.
- 48: Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber B, Barlev A, Mohty M. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. *J Med Econ*. 2016 Nov;19(11):1034-1039.
- 49: Rubio MT, Bouillié M, Bouazza N, Coman T, Trebeden-Nègre H, Gomez A, Suarez F, Sibon D, Brignier A, Paubelle E, Nguyen-Khoc S, Cavazzana M, Lantz O, Mohty M, Urien S, Hermine O. Pre-transplant donor CD4(-) invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. *Leukemia*. 2017 Apr;31(4):903-912. doi: 10.1038/leu.2016.281.
- 50: Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luyckx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple

51: Rosko AE, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Martino Bufarull R, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, Saber W. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. *Am J Hematol*. 2017 Jan;92(1):42-49.

52: Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, Kyrzcz-Krzemien S, Yakoub-Agha I, Aljurf M, Wu D, Michallet M, Arnold R, Mohty M, Nagler A. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica*. 2017 Jan;102(1):139-149

53: Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, Or R, Bonifazi F, Aljurf M, Socié G, Passweg J, Giebel S, Mohty M, Nagler A. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Am J Hematol*. 2017 Jan;92(1):18-22.

54: Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A. Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. *Bone Marrow Transplant*. 2017 Feb;52(2):238-244.

55: Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler A. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. *J Hematol Oncol*. 2016 Sep 17;9(1):89.

56: Saraceni F, Labopin M, Gorin NC, Blaise D, Tabrizi R, Volin L, Cornelissen J, Cahn JY, Chevallier P, Craddock C, Wu D, Huynh A, Arcese W, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. *J Hematol Oncol*. 2016 Sep 2;9(1):79.

57: Mohty M, Malard F, Blaise D, Milpied N, Socié G, Huynh A, Reman O, Yakoub-Agha I, Furst S, Guillaume T, Tabrizi R, Vigouroux S, Peterlin P, El-Cheikh J, Moreau P, Labopin M, Chevallier P. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. *Haematologica*. 2017 Jan;102(1):184-191.

58: Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron

A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. *Blood*. 2016 Oct 13;128(15):1979-1986.

59: DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kambale RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Papham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. *Bone Marrow Transplant*. 2017 Feb;52(2):173-182.

60: Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Féger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, Delhommeau F. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. *Nat Commun*. 2016 Aug 18;7:12475.

61: Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voltaire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P. Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients. *Semin Hematol*. 2016 Jul;53(3):216-7.

62: Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. *J Hematol Oncol*. 2016 Aug 3;9(1):65.

63: Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. *Biol Blood Marrow Transplant*. 2016 Nov;22(11):1915-1925.

64: Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarría E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. *Biol Blood Marrow Transplant*. 2016 Oct;22(10):1874-82.

65: Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A. Use of tyrosine kinase

inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer*. 2016 Oct;122(19):2941-51.

66: Baron F, Ruggeri A, Beohou E, Labopin M, Sanz G, Milpied N, Michallet M, Bacigalupo A, Blaise D, Sierra J, Socié G, Cornelissen JJ, Schmid C, Giebel S, Gorin NC, Esteve J, Ciceri F, Savani BN, Mohty M, Gluckman E, Nagler A. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. *Oncotarget*. 2016 Jul 12;7(28):43027-43038.

67: Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlisch PS, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. *Haematologica*. 2016 Sep;101(9):1120-7.

68: Grain A, Sirvent A, Strullu M, Françoise M, Mohty M, Guillaume T, Chevallier P, Riolland F. Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC). *Leuk Lymphoma*. 2016 Dec;57(12):2937-2941..

69: DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Papham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE; CIBMTR Late Effects and Quality of Life Working Committee; EBMT Complications and Quality of Life Working Party. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1493-503.

70: Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2016 Jul;51(7):906-12

71: Tsirogotis P, Danylesko I, Gkirkas K, Shem-Tov N, Yerushalmi R, Stamouli M, Avigdor A, Spyridonidis A, Gauthier J, Goldstein G, Apostolidis J, Mohty M, Shimoni A, Nagler A. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2016 Oct;51(10):1313-1317.

72: Lamarthée B, Malard F, Saas P, Mohty M, Gaugler B. Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. *Front Immunol*. 2016 Apr 19;7:148.

- 73: Dietrich S, Finel H, Martinez C, Tischer J, Blaise D, Chevallier P, Castagna L, Milpied N, Bacigalupo A, Corradini P, Mohty M, Sanz M, Hausmann A, Montoto S, Robinson S, Boumendil A, Sureda A, Dreger P. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. *Leukemia*. 2016 Oct;30(10):2086-2089
- 74: Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Talbot JN, Garderet L. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. *Eur J Nucl Med Mol Imaging*. 2016 Oct;43(11):1995-2004
- 75: Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, Moreau P, Mohty M, Campion L, Chevallier P. Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1473-9.
- 76: Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. *Leukemia*. 2016 Oct;30(10):2047-2054.
- 77: Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillermin G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. *Bone Marrow Transplant*. 2016 Sep;51(9):1184-90.
- 78: Byrne M, Savani BN, Mohty M, Nagler A. Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Exp Hematol*. 2016 Jul;44(7):567-73
- 79: Michel G, Galambrun C, Sirvent A, Pochon C, Bruno B, Jubert C, Loundou A, Yakoub-Agha I, Milpied N, Lutz P, Marie-Cardine A, Gandemer V, Blaise D, Michallet M, Riolland F, Renard C, Oudin C, Esmiol S, Seux M, Baumstarck K, Mohty M, Rocha V, Dalle JH. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. *Blood*. 2016 Jun 30;127(26):3450-7.
- 80: Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, Shaw BE, Majhail NS, Mohty M, Savani BN. Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1368-75

81: Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte RF, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. *J Clin Oncol.* 2016 Jul 1;34(19):2212-20.

82: Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, Emmanuel K, Moifar F, Pirich C, Langsteger W, Bytyqi A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M, Beyer T, Herrmann K, Czernin J, Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A, Mayerhöfer ME, Hartenbach M, Hacker M, Beyer T, Binzel K, Magnussen R, Wei W, Knopp MU, Flanigan DC, Kaeding C, Knopp MV, Leisser A, Nejbat M, Hartenbach M, Kramer G, Krainer M, Hacker M, Haug A, Lehnert W, Schmidt K, Kimiaei S, Bronzel M, Kluge A, Wright CL, Binzel K, Zhang J, Wuthrick E, Maniawski P, Knopp MV, Blaickner M, Rados E, Huber A, Dulovits M, Kulkarni H, Wiessalla S, Schuchardt C, Baum RP, Knäusl B, Georg D, Bauer M, Wulkersdorfer B, Wadsak W, Philippe C, Haslacher H, Zeitlinger M, Langer O, Bauer M, Feldmann M, Karch R, Wadsak W, Zeitlinger M, Koepf MJ, Asselin MC, Patariaia E, Langer O, Zeilinger M, Philippe C, Dumanic M, Pichler F, Pilz J, Hacker M, Wadsak W, Mitterhauser M, Nics L, Steiner B, Hacker M, Mitterhauser M, Wadsak W, Traxl A, Wanek T, Kryeziu K, Mairinger S, Stanek J, Berger W, Kuntner C, Langer O, Mairinger S, Wanek T, Traxl A, Krohn M, Stanek J, Filip T, Sauberer M, Kuntner C, Pahnke J, Langer O, Svatoněk D, Denk C, Wilkovič M, Wanek T, Filip T, Kuntner-Hannes C, Fröhlich J, Mikula H, Denk C, Svatoněk D, Wanek T, Mairinger S, Stanek J, Filip T, Fröhlich J, Mikula H, Kuntner-Hannes C, Balber T, Singer J, Fazekas J, Rami-Mark C, Berroterán-Infante N, Jensen-Jarolim E, Wadsak W, Hacker M, Viernstein H, Mitterhauser M, Denk C, Svatoněk D, Sohr B, Mikula H, Fröhlich J, Wanek T, Kuntner-Hannes C, Filip T, Pfaff S, Philippe C, Mitterhauser M, Hartenbach M, Hacker M, Wadsak W, Wanek T, Halilbasic E, Visentin M, Mairinger S, Stieger B, Kuntner C, Trauner M, Langer O, Lam P, Aistleitner M, Eichinger R, Artner C, Eidherr H, Vraka C, Haug A, Mitterhauser M, Nics L, Hartenbach M, Hacker M, Wadsak W, Kvaternik H, Müller R, Hausberger D, Zink C, Aigner RM, Cossío U, Asensio M, Montes A, Akhtar S, Te Welscher Y, van Nostrum R, Gómez-Vallejo V, Llop J, VandeVyver F, Barclay T, Lippens N, Troch M, Hehenwarter L, Egger B, Holzmannhofer J, Rodrigues-Radischat M, Pirich C, Pötsch N, Rausch I, Wilhelm D, Weber M, Furtner J, Karanikas G, Wöhrer A, Mitterhauser M, Hacker M, Traub-Weidinger T, Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Garderet L, Talbot JN, Stanzel S, Pregartner G, Schwarz T, Bjelic-Radisic V, Liegl-Atzwanger B, Aigner R, Stanzel S, Quehenberger F, Aigner RM, Marković AK, Janković M, Jerković VM, Paskaš M, Pupić G, Džodić R, Popović D, Fornito MC, Familiari D, Koranda P, Polzerová H, Metelková I, Henzlová L, Formánek R, Buriánková E, Kamínek M, Thomson WH, Lewis C, Thomson WH, O'Brien J, James G, Notghi A, Huber H, Stelzmüller I, Wunn R, Mandl M, Fellner F, Lamprecht B, Gabriel M, Fornito MC, Leonardi G, Thomson WH, O'Brien J, James G, Hudzietzová J, Sabol J, Fülöp M. 32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016. *EJNMMI Res.* 2016 Apr;6(Suppl 1):32.

83: Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, Wang H, Zhang MJ, Weisdorf D, Douer D, Rowe JM, Polge E, Esteve J, Nagler A, Mohty M, Tallman MS. Autologous transplant remains the preferred therapy for relapsed APL in CR2. *Bone Marrow Transplant.* 2016 Sep;51(9):1180-3.

84: Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I, Piemontese S, Polge E, Houhou M, Huang XJ, Mohty M, Nagler A, Gorin NC; Acute Leukemia Working Party of the EBMT. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. *Haematologica*. 2016 Aug;101(8):e352-4

85: Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2016 Jul;101(7):879-83.

86: Clark CA, Savani M, Mohty M, Savani BN. What do we need to know about allogeneic hematopoietic stem cell transplant survivors? *Bone Marrow Transplant*. 2016 Aug;51(8):1025-31.

87: Fuji S, Rovó A, Ohashi K, Griffith M, Einsele H, Kapp M, Mohty M, Majhail NS, Engelhardt BG, Tichelli A, Savani BN. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. *Bone Marrow Transplant*. 2016 Aug;51(8):1041-9.

88: Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerme G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). *Bone Marrow Transplant*. 2016 Jul;51(7):928-32.

89: Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerme G, Bordessoule D, Mohty M, Nagler A. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Oncotarget*. 2016 May 10;7(19):27255-66.

90: Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, Pigneux A, Bosi A, Veelken J, Ferrara F, Schaap N, Lemoli RM, Cornelissen JJ, Beohou E, Nagler A, Mohty M. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Cancer*. 2016 Jun 15;122(12):1880-7.

91: Sengsayadeth S, Savani BN, Blaise D, Mohty M. Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. *Semin Hematol*. 2016 Apr;53(2):111-4.

- 92: Savani BN, Mohty M. Introduction: Why alternative donor transplantation and what are the different options and current challenges? *Semin Hematol.* 2016 Apr;53(2):55-6.
- 93: El Cheikh J, Sfumato P, Sobh M, Fegueux N, Mohty M, Vigouroux S, Beguin Y, Yakoub-Agha I, Socié G, Cornillon J, Mercier M, Bay JO, Blaise D, Michallet M, Peffault de Latour R. Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC). *Haematologica.* 2016 Jun;101(6):e262-5.
- 94: Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, Bacigalupo A, Arcese W, Koc Y, Beelen D, Gülbas Z, Wu D, Santarone S, Tischer J, Afanasyev B, Schmid C, Giebel S, Mohty M, Nagler A. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. *J Hematol Oncol.* 2016 Mar 15;9:25.
- 95: Savani BN, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. *Haematologica.* 2016 Jun;101(6):773-80.
- 96: Shouval R, Labopin M, Unger R, Giebel S, Ciceri F, Schmid C, Esteve J, Baron F, Gorin NC, Savani B, Shimoni A, Mohty M, Nagler A. Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. *PLoS One.* 2016 Mar 4;11(3):e0150637.
- 97: Malard F, Labopin M, Chevallier P, Guillaume T, Duquesne A, Riolland F, Derenne S, Peterlin P, Leauté AG, Brissot E, Gregoire M, Moreau P, Saas P, Gaugler B, Mohty M. Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. *Blood.* 2016 Apr 7;127(14):1828-35.
- 98: Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. *Bone Marrow Transplant.* 2016 Jun;51(6):786-92.
- 99: Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, Horowitz M, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini MC, Kadera Y, Apperley J, Seber A, Gratwohl A. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. *Bone Marrow Transplant.* 2016 Jun;51(6):778-85.

- 100: Vozy A, Cohen M, Rubio MT, Rostaing-Rigattieri S, Mohty M, Mamez AC. Medullar toxicity after prolonged nitrous oxide exposure: an unexpected cause of bone marrow failure post allogeneic transplant. *Bone Marrow Transplant*. 2016 Jun;51(6):876-8.
- 101: Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, Bories D, Marzac C, Fava F, Legrand O, Mohty M, Douay L, Delhommeau F. Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. *Leukemia*. 2016 Aug;30(8):1756-9.
- 102: Giebel S, Labopin M, Ibatci A, Browne P, Czerw T, Socie G, Unal A, Kyrzcz-Krzemien S, Bacigalupo A, Goker H, Potter M, Furness CL, McQuaker G, Beelen D, Milpied N, Campos A, Craddock C, Nagler A, Mohty M. Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. *Oncologist*. 2016 Mar;21(3):377-83.
- 103: Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, de Elvira CR, Snowden JA, Passweg J, Apperley J, Niederwieser D, Stijnen T, Brand R; Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT) and the European Leukemia Net (ELN). Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. *EBioMedicine*. 2015 Nov 19;2(12):2101-9.
- 104: Malard F, Gaugler B, Lamarthee B, Mohty M. Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease. *Mucosal Immunol*. 2016 Mar;9(2):299-308.
- 105: Chaturvedi S, Neff A, Nagler A, Savani U, Mohty M, Savani BN. Venous thromboembolism in hematopoietic stem cell transplant recipients. *Bone Marrow Transplant*. 2016 Apr;51(4):473-8.
- 106: Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. *Am J Hematol*. 2016 Jun;91(4):366-70.
- 107: Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D; Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. *Lancet Haematol*. 2015 Mar;2(3):e91-100. doi: 10.1016/S2352-3026(15)00028-9. Epub 2015 Feb 27. Erratum in: *Lancet Haematol*. 2015 May;2(5):e184.
- 108: Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, Kyrzcz-Krzemien S, Volin L, Anagnostopoulos A, Aljurf M, Beelen DW, Vigouroux S, Milpied N, Suarez F, Mohty M. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre,

registry analysis. *Lancet Haematol.* 2015 Sep;2(9):e384-92.

109: Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. *Bone Marrow Transplant.* 2016 Apr;51(4):610-1.

110: Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. *Bone Marrow Transplant.* 2016 Feb;51(2):267-72.

111: Cahu X, Labopin M, Giebel S, Aljurf M, Kyrzcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. *Bone Marrow Transplant.* 2016 Mar;51(3):351-7

112: Poloméni A, Lapusan S, Bompont C, Rubio MT, Mohty M. The impact of allogeneic-hematopoietic stem cell transplantation on patients' and close relatives' quality of life and relationships. *Eur J Oncol Nurs.* 2016 Apr;21:248-56. doi: 10.1016/j.ejon.2015.10.011. Epub 2015 Nov 18. PMID: 26602410.

113: Le Bourgeois A, Malard F, Chevallier P, Urbistandoy G, Guillaume T, Delaunay J, Peterlin P, Lemarchand P, Germaud P, Mohty M, Moreau P, Chambellan A. Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases. *Bone Marrow Transplant.* 2016 Apr;51(4):589-92.

114: Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Bone Marrow Transplant.* 2016 Mar;51(3):358-64.

115: Brands-Nijenhuis AV, Labopin M, Schouten HC, Volin L, Socié G, Cornelissen JJ, Huynh A, Ljungman P, Malard F, Esteve J, Nagler A, Mohty M. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. *Haematologica.* 2016 Feb;101(2):248-55.

116: Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, Arnold R, Afanasyev B, Vigouroux S, Milpied N, Hallek M, Cornelissen JJ, Schwerdtfeger

R, Polge E, Baron F, Esteve J, Gorin NC, Schmid C, Giebel S, Mohty M, Nagler A. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. *Haematologica*. 2016 Feb;101(2):256-62

117: Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber BL, Barlev A, Mohty M. Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients with Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in France. *Value Health*. 2015 Nov;18(7):A443.

118: Ravinet A, Cabrespine A, Socié G, Milpied N, Yakoub Agha I, Nguyen S, Michallet M, Menard AL, Maillard N, Mohty M, Suarez F, Huynh A, Marchand T, Deteix C, Cassuto JP, Maury S, Chevallier P, Reman O, Peffault de Latour R, Bay JO. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Transplantation*. 2016 Aug;100(8):1732-9.

119: Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? *Blood*. 2015 Dec 17;126(25):2713-9.

120: Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. *Bone Marrow Transplant*. 2016 Mar;51(3):418-23.

121: Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A, Rambaldi A, Bonifazi F, Bosi A, Sierra J, Yakoub-Agha I, Santasusana JM, Gluckman E, Nagler A. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. *J Hematol Oncol*. 2015 Oct 6;8:107.

122: Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J, Kanz L, Blaise D, Dreger P, Held G, Arnold R, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. *Bone Marrow Transplant*. 2016 Feb;51(2):186-93.

123: Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua

D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E; American Society of Blood and Marrow Transplantation; European Society of Blood and Marrow Transplantation; Blood and Marrow Transplant Clinical Trials Network; International Myeloma Working Group Consensus Conference. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2015 Dec;21(12):2039-51.

124: Bazarbachi A, Labopin M, Kharfan-Dabaja MA, Schwerdtfeger R, Volin L, Bourhis JH, Socié G, Daguindau E, Gedde-Dahl T, Rambaldi A, Karas M, Schlimok G, Blaise D, Chevallier P, Malard F, Schmid C, Esteve J, Nagler A, Mohty M. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. *Haematologica*. 2016 Jan;101(1):e34-7.

125: Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, Michallet M, Santarone S, Ehninger G, Polge E, Laszlo D, Schmid C, Nagler A, Mohty M. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥ 10 years. *Bone Marrow Transplant*. 2015 Dec;50(12):1508-12.

126: Li Z, Mewawalla P, Stratton P, Yong AS, Shaw BE, Hashmi S, Jagasia M, Mohty M, Majhail NS, Savani BN, Rovó A. Sexual health in hematopoietic stem cell transplant recipients. *Cancer*. 2015 Dec 1;121(23):4124-31.

127: Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? *Bone Marrow Transplant*. 2015 Nov;50(11):1411-5.

128: Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. *Bone Marrow Transplant*. 2015 Dec;50(12):1542-50.

129: Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, Contentin N, Mohty M, Nguyen S, Lioure B, Raus N, Peffault de Latour R, Yakoub-Agha I, Reman O; SFGM-TC group. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. *Bone Marrow Transplant*. 2015 Dec;50(12):1586-8.

130: Yong AS, Brissot E, Rubinstein S, Savani BN, Mohty M. Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia. *Expert Rev Hematol*. 2015 Dec;8(6):785-97

131: Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A,

Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. *Transpl Infect Dis*. 2015 Dec;17(6):822-30

132: Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. *Blood*. 2015 Oct 22;126(17):2062-9

133: Ringdén O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, Ghavamzadeh A, Hamladji RM, Schmid C, Nagler A, Mohty M. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? *Leukemia*. 2016 Feb;30(2):447-55

134: Gorin NC, Giebel S, Labopin M, Savani BN, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. *Bone Marrow Transplant*. 2015 Dec;50(12):1495-502.

135: Battipaglia G, Ruggeri A, Brissot E, Mamez AC, Malard F, Belhocine R, Vekhoff A, Giannotti F, Ledraa T, Labopin M, Rubio MT, Mohty M. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2015 Dec;50(12):1574-7.

136: Sicre de Fontbrune F, Moignet A, Beaupain B, Suarez F, Galicier L, Socié G, Varet B, Coppo P, Michel M, Pautas C, Oksenhendler E, Lengline E, Terriou L, Moreau P, Chantepie S, Casadevall N, Michot JM, Gardembas M, Michallet M, Croisille L, Audrain M, Bellanné-Chantelot C, Donadieu J, Lamy T; French Severe Chronic Neutropenia Registry. Severe chronic primary neutropenia in adults: report on a series of 108 patients. *Blood*. 2015 Oct 1;126(14):1643-50.

137: Guièze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M, Vigouroux S, Beguin Y, Blaise D, El Cheikh J, Roos-Weil D, Thiebaut A, Rohrlich PS, Huynh A, Cornillon J, Contentin N, Suarez F, Lioure B, Mohty M, Maillard N, Clement L, François S, Guillerm G, Yakoub-Agha I. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies. *Biol Blood Marrow Transplant*. 2016 Feb;22(2):240-7

138: Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. *J Clin Oncol*. 2015 Oct 1;33(28):3144-51.

139: Lamarthée B, Malard F, Gamonet C, Bossard C, Couturier M, Renauld JC, Mohty M, Saas P, Gaugler B. Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation

140: Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. *Haematologica.* 2015 Jul;100(7):859-69.

141: Brissot E, Mohty M. Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation? *Semin Hematol.* 2015 Jul;52(3):223-31.

142: Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G, Blaise D, Craddock C, Milpied N, Bacher U, Malard F, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party EBMT. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). *Leukemia.* 2015 Dec;29(12):2375-81.

143: Boussem I, Sokol H, Aractingi S, Georges O, Hoyeau-Idrissi N, Hugot JP, Mohty M, Rubio MT. Inflammatory bowel disease after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2015 Oct;50(10):1365-6

144: Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2015 Aug;50(8):1063-8.

145: Poiré X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, Milpied N, Cahn JY, Yacoub-Agha I, van Imhoff GW, Michallet M, Michaux L, Nagler A, Mohty M. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). *Am J Hematol.* 2015 Aug;90(8):719-24.

146: Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji RM, Nagler A, Mohty M. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Leuk Res.* 2015 Sep;39(9):933-7

147: Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. *Biol Blood Marrow Transplant.* 2015 Aug;21(8):1343-59.

148: Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M. A nationwide survey of the use of plexixafor in patients with lymphoid malignancies who

mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs. *Transfusion*. 2015 Sep;55(9):2149-57.

149: Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, Tabrizi R, Huyn A, Buzyn A, Socié G, Vincent L, Guilhot F, Yakoub-Agha I, Lenain P, François S, Beckerich F, Lioure B, Bulabois CE, Deconinck E; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Biol Blood Marrow Transplant*. 2015 Aug;21(8):1452-9.

150: Mohty M, Richardson PG, McCarthy PL, Attal M. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? *Bone Marrow Transplant*. 2015 Aug;50(8):1024-9.

151: Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M; Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology working party-EBMT; ALWP-EBMT study. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. *Leukemia*. 2015 Sep;29(9):1891-900

152: Chakraborty R, Savani BN, Litzow M, Mohty M, Hashmi S. A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties. *Cancer*. 2015 Jul 15;121(14):2303-13.

153: Mohty M, Malard F. To RIC or not to RIC: that is the question. *Leukemia*. 2015 Jul;29(7):1450-1

154: Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T, Gregoire M, Gaugler B, Mohty M. Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2015 Aug;21(8):1431-6.

155: D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prévot O, Garfa-Traoré M, Suarez F, Trebeden-Nègre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT. G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease. *Sci Transl Med*. 2015 Apr 1;7(281):281ra42

156: Arbez J, Saas P, Lamarthée B, Malard F, Couturier M, Mohty M, Gaugler B. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease. *Cytotherapy*. 2015 Jul;17(7):948-55

157: Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, de Rosa G, Volin L, Beelen D, Veelken H, Schaap NP, Kuball J, Cornelissen J, Nagler A, Mohty M; Acute Leukemia Working Party. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a

retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Eur J Haematol.* 2016 Jan;96(1):90-7.

158: El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, Zibara K, Darwiche N, Mohty M, Dombret H, Fenaux P, de Thé H, Bazarbachi A. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. *Blood.* 2015 May 28;125(22):3447-54.

159: Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Duarte RF, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Pagluica T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant.* 2015 Jun;50(6):781-9

160: Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? *Bone Marrow Transplant.* 2015 Jul;50(7):899-903.

161: Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. *Bone Marrow Transplant.* 2015 Aug;50(8):1037-56.

162: Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN; American Society for Blood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2015 Jul;21(7):1155-66.

163: Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica.* 2015 May;100(5):683-9.

164: Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, Beguin Y, N'guyen S, Bories P, Blaise D, Cornillon J, Clavert A, Mohty M, Huynh A, Thiébaud-Bertrand A, Vigouroux S, Duhamel A, Yakoub-Agha I. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy. *Transplantation.* 2015 Aug;99(8):1672-80.

165: Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

166: Mohty M, Gaugler B. A bit of sweetness for GVHD prevention. *Blood*. 2015 Feb 26;125(9):1364-5.

167: Malard F, Milpied N, Blaise D, Chevallier P, Michallet M, Lioure B, Clément L, Hicheri Y, Cordonnier C, Huynh A, Yakoub-Agha I, Peffault de Latour R, Mohty M. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Biol Blood Marrow Transplant*. 2015 Jun;21(6):1059-67.

168: Basak GW, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, Beguin Y, Lang P, Koenecke C, Sykora KW, Te Boome L, van Biezen A, van der Werf S, Mohty M, de Witte T, Marsh J, Dreger P, Kröger N, Duarte R, Ruutu T. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. *Am J Transplant*. 2015 Mar;15(3):705-14

169: Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. *Bone Marrow Transplant*. 2015 Apr;50(4):476-82.

170: Gorin NC, Labopin M, Piemontese S, Arcese W, Santarone S, Huang H, Meloni G, Ferrara F, Beelen D, Sanz M, Bacigalupo A, Ciceri F, Mailhol A, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. *Haematologica*. 2015 Apr;100(4):558-64.

171: Hebraud B, Magrangeas F, Cleyne A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. *Blood*. 2015 Mar 26;125(13):2095-100.

172: Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis JH, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte TM, Rocha V, Kroger N. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. *Biol Blood Marrow Transplant*. 2015 Mar;21(3):489-95.

173: Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkopp G, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia

chromosome positive acute lymphoblastic leukemia. *Haematologica*. 2015 Mar;100(3):392-9.

174: Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2015 Jun;21(6):959-70.

175: Shem-Tov N, Labopin M, Moukhtari L, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Shimoni A, Nagler A, Mohty M. Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Oncologist*. 2015 Jan;20(1):50-5.

176: Mohty M, Malard F. Thymoglobulin and an unexpected outbreak of Epstein-Barr virus. *Biol Blood Marrow Transplant*. 2015 Jan;21(1):198.

177: Savani BN, Mohty M. Bone marrow transplantation. Preface. *Hematol Oncol Clin North Am*. 2014 Dec;28(6):xiii-xv.

178: Kempf E, Hirsch P, Labopin M, Viguié F, Isnard F, Tang R, Marzac C, Marie JP, Mohty M, Legrand O. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. *Leuk Res*. 2014 Dec;38(12):1425-9.

179: Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G, Arcese W, Nagler A, Mohty M; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. *Leukemia*. 2015 May;29(5):1069-75.

180: Blaise D, Devillier R, Lecoroller-Sorriano AG, Boher JM, Boyer-Chammard A, Tabrizi R, Chevallier P, Fegueux N, Sirvent A, Michallet M, Bay JO, Fürst S, El-Cheikh J, Vincent L, Guillaume T, Regny C, Milpied N, Castagna L, Mohty M. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. *Haematologica*. 2015 Feb;100(2):269-74.

181: Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Cancer*. 2015 Apr 1;121(7):1048-55

182: Brissot E, Bossard C, Malard F, Braudeau C, Chevallier P, Guillaume T, Delaunay J, Josien R, Gregoire M, Gaugler B, Mohty M. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease. *J Leukoc Biol*. 2015 Feb;97(2):227-35.

183: Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Harousseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. *Ann Hematol*. 2015 Apr;94(4):663-9.

184: Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubrulle V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. *Ann Oncol*. 2015 Feb;26(2):386-92.

185: Detrait MY, Morisset S, Peffault de Latour R, Yakoub-Agha I, Crocchiolo R, Tabrizi R, Bay JO, Chevalier P, Barraco F, Raus N, Vigouroux S, Magro L, Mohty M, Milpied N, Blaise D, Socié G, Michallet M. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Bone Marrow Transplant*. 2015 Feb;50(2):253-8.

186: Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. *Ann Oncol*. 2015 Jan;26(1):193-8.

187: Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T, Mosnier JF, Galmiche JP, Mohty M. Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. *United European Gastroenterol J*. 2014 Jun;2(3):206-15

188: Pascal L, Mohty M, Ruggeri A, Tucunduva L, Milpied N, Chevallier P, Tabrizi R, Labalette M, Gluckman E, Labopin M, Yakoub-Agha I. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. *Bone Marrow Transplant*. 2015 Jan;50(1):45-50.

189: Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M, Chevallier P. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. *Cancer*. 2015 Feb 15;121(4):562-9.

190: Ballinger TJ, Savani BN, Gupta V, Kroger N, Mohty M. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. *Eur J Haematol*. 2015 Feb;94(2):115-9

191: Lapusan S, Yong A, Savani BN, Mohty M. Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points. *Eur J Haematol*. 2015 Aug;95(2):103-12

192: Mohty M, Malard F, Savani BN. High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? *Biol Blood Marrow Transplant*. 2015 Apr;21(4):620-4.

193: Chevallier P, Labopin M, Socie G, Rubio MT, Blaise D, Vigouroux S, Huynh A, Michallet M, Bay JO, Maury S, Yakoub-Agha I, Fegueux N, Deconinck E, Contentin N, Maillard N, Bulabois CE, Francois S, Oumedaly R, Raus N, Mohty M. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. *Eur J Haematol.* 2015 May;94(5):449-55.

194: El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, Colombat P, Biron P, Tilly H, Pfreundschuh M, Cordonnier C, Sureda A, Cahn JY, Vernant JP, Gribben J, Cook G, Haynes AP, Ferrant A, Finel H, Montoto S, Dreger P; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. *Ann Oncol.* 2014 Nov;25(11):2224-9.

195: Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. *Biol Blood Marrow Transplant.* 2015 Jan;21(1):180-4.

196: Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin®) in solid organ transplants, stem cell transplants and autoimmunity. *Drugs.* 2014 Sep;74(14):1605-34.

197: Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerme G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, François S, Peffault de Latour R, Yakoub-Agha I, Mohty M. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). *Eur J Haematol.* 2015 Mar;94(3):265-9.

198: Oudin C, Chevallier P, Furst S, Guillaume T, El Cheikh J, Delaunay J, Castagna L, Faucher C, Granata A, Devillier R, Chabannon C, Esterni B, Vey N, Mohty M, Blaise D. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. *Haematologica.* 2014 Nov;99(11):1762-8.

199: Le Bourgeois A, Labopin M, Guillaume T, Delaunay J, Foucher Y, Tessoulin B, Malard F, Ayari S, Peterlin P, Derenne S, Herry P, Cesbron A, Gagne K, Lodé L, Illiaquer M, Imbert-Marcille BM, Le Gouill S, Moreau P, Mohty M, Chevallier P. Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. *Exp Hematol.* 2014 Nov;42(11):945-54.

200: Brissot E, Gomez A, Aline-Fardin A, Lalande V, Lapusan S, Isnard F, Legrand O, Meynard JL, Rubio MT, Mohty M. Report of disseminated Mycobacterium

haemophilum infection after double cord blood allo-SCT. *Bone Marrow Transplant.* 2014 Oct;49(10):1347-8.

201: Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, Nagler A, Mohty M, Sureda A, Dreger P, Hermine O. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. *Bone Marrow Transplant.* 2014 Oct;49(10):1266-8

202: Hwang YY, Mohty M, Chim CS. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond. *Hematology.* 2015 Mar;20(2):61-71.

203: Tucunduva L, Ruggeri A, Sanz G, Furst S, Socié G, Michallet M, Arcese W, Milpied N, Yakoub-Agha I, Linkesch W, Cornelissen J, Mannone L, Iori AP, Ribera JM, Sanz J, Montesinos P, Purtil D, Labopin M, Gluckman E, Mohty M, Rocha V. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2014 Jul;49(7):887-94.

204: Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. *Bone Marrow Transplant.* 2014 Sep;49(9):1170-5.

205: Tucunduva L, Ruggeri A, Sanz G, Furst S, Cornelissen J, Linkesch W, Mannone L, Ribera JM, Veelken H, Yakoub-Agha I, González Valentín ME, Schots R, Arcese W, Montesinos P, Labopin M, Gluckman E, Mohty M, Rocha V. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation. *Br J Haematol.* 2014 Sep;166(5):749-57.

206: Hirsch P, Labopin M, Viguié F, Perot C, Isnard F, Mamez AC, Bilhou-Nabera C, Marzac C, Delhommeau F, Lapusan S, Marie JP, Mohty M, Legrand O. Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. *Leuk Res.* 2014 Aug;38(8):907-12

207: Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de La Tour RP, Vigouroux S, El-Cheikh J, Blaise D, Michallet M, Bilger K, Milpied N, Moreau P, Mohty M. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. *Haematologica.* 2014 Sep;99(9):1486-91.

208: Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn JY, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay JO, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A; Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT). Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. *Biol Blood Marrow Transplant.* 2014 Nov;20(11):1841-6.

- 209: Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. *Leukemia*. 2015 Jan;29(1):51-7.
- 210: Damaj G, Mohty M, Robin M, Michallet M, Chevallier P, Beguin Y, Nguyen S, Bories P, Blaise D, Maillard N, Rubio MT, Fegueux N, Cornillon J, Clavert A, Huynh A, Adès L, Thiébaud-Bertrand A, Hermine O, Vigouroux S, Fenaux P, Duhamel A, Yakoub-Agha I. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Biol Blood Marrow Transplant*. 2014 Sep;20(9):1349-55
- 211: Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giral S, Carpenter PA. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2014 Sep;20(9):1262-73.
- 212: Nagler A, Labopin M, Gorin NC, Ferrara F, Sanz MA, Wu D, Gomez AT, Lapusan S, Irrera G, Guimaraes JE, Sousa AB, Carella AM, Vey N, Arcese W, Shimoni A, Berger R, Rocha V, Mohty M. Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014 Aug;99(8):1380-6.
- 213: Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, Gorin NC, Labopin M, Nagler A, Schmid C, Mohty M. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Cancer*. 2014 Sep 1;120(17):2760-5
- 214: Ringdén O, Labopin M, Solders M, Beelen D, Arnold R, Ehninger G, Milpied N, Niederwieser D, Hamladji RM, Kyrz-Krzemien S, Ganser A, Socié G, Stelljes M, Volin L, Craddock C, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia? *Transplantation*. 2014 Sep 15;98(5):569-77.
- 215: Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, de Witte TM, Kröger N, Ruutu T. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. *Leukemia*. 2014 Nov;28(11):2235-40
- 216: Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, Solh HE, Atsuta Y, Szer J, Kodera Y, Niederwieser D, Gratwohl A, Horowitz MM. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. *Bone Marrow Transplant*. 2014 Aug;49(8):1016-21
- 217: Malard F, Chevallier P, Guillaume T, Delaunay J, Riolland F, Harousseau JL, Moreau P, Mechinaud F, Milpied N, Mohty M. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. *Biol Blood Marrow Transplant*. 2014 Aug;20(8):1217-23.

- 218: Malard F, Mohty M. New insight for the diagnosis of gastrointestinal acute graft-versus-host disease. *Mediators Inflamm.* 2014;2014:701013.
- 219: Hirsch P, Qassa G, Marzac C, Tang R, Perrot JY, Isnard F, Mohty M, Marie JP, Legrand O. Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations. *Leuk Lymphoma.* 2015 Jan;56(1):147-50
- 220: Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Dumas PY, Foa R, Attal M, Schaap N, Michallet M, Bonmati C, Veelken H, Mohty M. Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2014 Jul;49(7):950-4.
- 221: Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldès C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciú S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2014 Jul;49(7):865-72.
- 222: Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A; European Society for Blood and Marrow Transplantation EBMT. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. *Bone Marrow Transplant.* 2014 Jun;49(6):744-50.
- 223: Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, Vigouroux S, Blaise D, Mariette C, Bilger K, Robin M, Yakoub-Agha I, Peffault de Latour R, Mohty M. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). *Bone Marrow Transplant.* 2014 Jun;49(6):756-60.
- 224: Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. *Haematologica.* 2014 Mar;99(3):408-16.
- 225: Illiaquer M, Malard F, Guillaume T, Imbert-Marcille BM, Delaunay J, Le Bourgeois A, Rimbert M, Bressollette-Bodin C, Precupanu C, Ayari S, Peterlin P, Moreau P, Mohty M, Chevallier P. Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation. *J Infect Dis.* 2014 Aug 15;210(4):567-70
- 226: Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. *Ann Hematol.* 2014 Feb;93(2):233-42
- 227: Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. *Bone Marrow Transplant.* 2014 May;49(5):628-33.

- 228: Dirou S, Malard F, Chambellan A, Chevallier P, Germaud P, Guillaume T, Delaunay J, Moreau P, Delasalle B, Lemarchand P, Mohty M. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. *Bone Marrow Transplant*. 2014 May;49(5):622-7.
- 229: Guillet S, Hirsch P, Marzac C, Mohty M, Marie JP, Legrand O. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia. *Leuk Lymphoma*. 2014 Nov;55(11):2646-8.
- 230: Tessoulin B, Delaunay J, Chevallier P, Loirat M, Ayari S, Peterlin P, Le Gouill S, Gastinne T, Moreau P, Mohty M, Guillaume T. Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2014 Apr;49(4):567-71.
- 231: Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2014 May;20(5):646-54.
- 232: Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2014 Mar;49(3):389-96.
- 233: Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased Th17/Treg ratio in chronic liver GVHD. *Bone Marrow Transplant*. 2014 Apr;49(4):539-44.
- 234: Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014 May;99(5):916-21
- 235: Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Cancer*. 2014 Mar 15;120(6):855-63.

- 236: Hu B, Vikas P, Mohty M, Savani BN. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. *Expert Rev Hematol.* 2014 Apr;7(2):301-15.
- 237: Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois CE, Maury S, Beguin Y, Bay JO, Blaise D, Maillard N, Guillermin G, Daguindeau E, Raus N, Mohty M. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Bone Marrow Transplant.* 2014 Mar;49(3):361-5
- 238: Wallet HL, Sobh M, Robin M, Fegueux N, Fürst S, Mohty M, Yakoub-Agha I, Marry E, Rocha V, Blaise D, Milpied N, Nicolini FE, Michallet M. First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes. *Exp Hematol.* 2014 Mar;42(3):161-2.
- 239: Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E. The effects of bortezomib on bone disease in patients with multiple myeloma. *Cancer.* 2014 Mar 1;120(5):618-23.
- 240: Labopin M, Gorin NC, Polge E, Socié G, Gurman G, Gluckman E, Jindra P, Poiré X, Schäfer-Eckart K, Ruutu T, Milone G, Arcese W, Mohty M, Rocha V; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. *Bone Marrow Transplant.* 2014 Mar;49(3):376-81
- 241: Giebel S, Labopin M, Gorin NC, Caillot D, Leguay T, Schaap N, Michallet M, Dombret H, Mohty M. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. *Eur J Cancer.* 2014 Jan;50(2):411-7.
- 242: Labopin M, Ruggeri A, Gorin NC, Gluckman E, Blaise D, Mannone L, Milpied N, Yakoub-Agha I, Deconinck E, Michallet M, Fegueux N, Socié G, Nguyen S, Cahn JY, de Revel T, Garnier F, Faucher C, Taright N, Kenzey C, Volt F, Bertrand D, Mohty M, Rocha V; Eurocord and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. *Haematologica.* 2014 Mar;99(3):535-40.
- 243: Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, Guillaume T, Delaunay J, Brissot E, Moreau P, Kraeber-Bodere F, Mohty M. 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. *Bone Marrow Transplant.* 2014 Jan;49(1):131-7.
- 244: Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau IW, Mohty M. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. *Blood.* 2013 Nov 7;122(19):3359-64. doi: 10.1182/blood-2013-05-499830. Epub 2013 Sep 13. PMID: 24037724.

- 245: Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, Yakoub-Agha I, Ribera JM, Mannone L, Sierra J, Mohty M, Solano C, Nabhan S, Arcese W, Gluckman E, Labopin M, Rocha V; Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. *Leukemia*. 2014 Apr;28(4):779-86.
- 246: Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau JL, Labussière H, Nicolini FE, Attal M, Moreau P, Mohty M, Blaise D, Avet-Loiseau H. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. *Exp Hematol*. 2013 Dec;41(12):1008-15.
- 247: Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Grégoire M, Gaugler B, Mohty M. Increased plasmacytoid dendritic cells and ROR γ t-expressing immune effectors in cutaneous acute graft-versus-host disease. *J Leukoc Biol*. 2013 Dec;94(6):1337-43
- 248: Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruoto T, Madrigal A, Johnsen HE; Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. *Biol Blood Marrow Transplant*. 2013 Dec;19(12):1670-6.
- 249: Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. *J Clin Oncol*. 2013 Oct 1;31(28):3549-56.
- 250: Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M; ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013 Oct;24 Suppl 6:vi133-7.
- 251: Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. *Ann Hematol*. 2014 Feb;93(2):233-42.
- 252: Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengelojev H, Finke J, Mohty M, Rio B, Petersen E, Guilhot F, Niederwieser D, Cornelissen JJ, Jindra P, Nagler A, Fegueux N, Schoemans H, Robinson S, Ruggeri A, Gluckman E, Canals C, Sureda A;

Eurocord-Netcord and the Lymphoma Working Party; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. *Haematologica*. 2014 Feb;99(2):370-7.

253: Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. *Bone Marrow Transplant*. 2014 Feb;49(2):168-73.

254: Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Fürst S, Mohty M, Deconinck E, Fouillard L, Bordigoni P, Rio B, Sirvent A, Renaud M, Dhedin N, Tabrizi R, Maury S, Buzyn A, Michel G, Maillard N, Cahn JY, Bay JO, Yakoub-Agha I, Huynh A, Schmidt-Tanguy A, Lamy T, Lioure B, Raus N, Marry E, Garnier F, Balère ML, Gluckman E, Rocha V, Socié G, Blaise D, Milpied N, Michallet M. Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. *Exp Hematol*. 2013 Nov;41(11):924-33.

255: Maury S, Balère-Appert ML, Pollichieni S, Oneto R, Yakoub-Agha I, Locatelli F, Dalle JH, Lanino E, Fischer A, Pession A, Huynh A, Barberi W, Mohty M, Risitano A, Milpied N, Socié G, Bacigalupo A, Marsh J, Passweg JR; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. *Am J Hematol*. 2013 Oct;88(10):868-73

256: Peffault de Latour R, Brunstein CG, Porcher R, Chevallier P, Robin M, Warlick E, Xhaard A, Ustun C, Larghero J, Dhedin N, Mohty M, Socié G, Weisdorf D. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. *Biol Blood Marrow Transplant*. 2013 Sep;19(9):1355-60.

257: Malard F, Fürst S, Loirat M, Chevallier P, El-Cheikh J, Guillaume T, Delaunay J, Le Gouill S, Moreau P, Blaise D, Mohty M. Effect of graft source on mismatched unrelated donor hematopoietic stem cell transplantation after reduced intensity conditioning. *Leukemia*. 2013 Nov;27(11):2113-7.

258: Gaugler B, Arbez J, Legouill S, Tiberghien P, Moreau P, Derenne S, Saas P, Mohty M. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. *Cytotherapy*. 2013 Jul;15(7):861-8

259: Mohty M, Brissot E, Savani BN, Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. *Biol Blood Marrow Transplant*. 2013 Oct;19(10):1416-20.

260: Kharfan-Dabaja MA, Nishihori T, Otrrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2013 Sep;19(9):1288-300.

261: Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A,

Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Blood and Marrow Transplantation. Hematopoietic SCT in Europe: data and trends in 2011. *Bone Marrow Transplant*. 2013 Sep;48(9):1161-7.

262: Marçais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillemin G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). *Haematologica*. 2013 Sep;98(9):1467-75.

263: Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruielle V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. *Biol Blood Marrow Transplant*. 2013 Jun;19(6):934-9.

264: Rocha V, Labopin M, Ruggeri A, Podestà M, Gallamini A, Bonifazi F, Sanchez-Guijo FM, Rovira M, Socie G, Baltadakis I, Michallet M, Deconinck E, Bacigalupo A, Mohty M, Gluckman E, Frasson F. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. *Transplantation*. 2013 May 27;95(10):1284-91. doi: 10.1097/TP.0b013e318288ca4d. PMID: 23507699.

265: Couturier M, Lamarthée B, Arbez J, Renauld JC, Bossard C, Malard F, Bonnefoy F, Mohty M, Perruche S, Tiberghien P, Saas P, Gaugler B. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. *Leukemia*. 2013 Jul;27(7):1527-37.

266: Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, Leone G, Abdel-Rahman F, Liso V, Hamidieh AA, Rasheed W, Ibrahim A, Alabdulaaly A, Kyrzcz-Krzemien S, Arnold R, Kharfan-Dabaja MA, Alimoghaddam K, Aljurf M, Mohty M. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBT) and European (EBMT) centers. *Bone Marrow Transplant*. 2013 Aug;48(8):1065-9.

267: Kröger N, Mohty M, Nagler A, Yi Q. Immunotherapy for multiple myeloma. *Clin Dev Immunol*. 2012;2012:797165.

268: Chevallier P, Robillard N, Illiaquer M, Esbelin J, Mohty M, Bodin-Bressollette C, Guillaume T, Stocco V, Auffray F, Derenne S, Planche L, Bene MC, Imbert-Marcille BM. Characterization of various blood and graft sources: a prospective series. *Transfusion*. 2013 Sep;53(9):2020-6.

269: Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E, Michallet M, Robin M, De Revel T, Bernard M, Vey N, Lioure B, Lapusan S, Tabrizi R, Bourhis JH, Huynh A, Beguin Y, Socié G, Dreyfus F, Fenaux P, Mohty M. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *Eur J Haematol*. 2013 May;90(5):355-64

- 270: Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, Roland V, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Chevallier P. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). *Eur J Haematol.* 2013 Mar;90(3):177-86.
- 271: Voswinkel J, Francois S, Simon JM, Benderitter M, Gorin NC, Mohty M, Fouillard L, Chapel A. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. *Clin Rev Allergy Immunol.* 2013 Oct;45(2):180-92
- 272: Antar A, Otrock ZK, Khafan-Dabaja M, Salem Z, Aractingi S, Mohty M, Bazarbachi A. Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2013 Jul;48(7):994-5.
- 273: Chevallier P, Robillard N, Illiaquer M, Esbelin J, Mohty M, Bodin-Bressollette C, Guillaume T, Stocco V, Auffray F, Derenne S, Planche L, Bene MC, Imbert-Marcille BM. HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective series. *J Clin Virol.* 2013 Apr;56(4):331-5
- 274: Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M; Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT). Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. *Bone Marrow Transplant.* 2013 Jun;48(6):761-70
- 275: Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. *Blood.* 2013 Jan 17;121(3):440-6
- 276: Chantepie SP, Mohty M, Tabrizi R, Robin M, Deconinck E, Buzyn A, Contentin N, Raus N, Lhéritier V, Reman O. Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Bone Marrow Transplant.* 2013 May;48(5):684-90.
- 277: Coman T, Bachy E, Michallet M, Socié G, Uzunov M, Bourhis JH, Lapusan S, Brebion A, Vigouroux S, Maury S, François S, Huynh A, Lioure B, Yakoub-Agha I, Hermine O, Milpied N, Mohty M, Rubio MT. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. *Haematologica.* 2013 May;98(5):776-83

278: Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guilleum G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. *J Clin Oncol*. 2012 Dec 20;30(36):4533-40.

279: Michallet M, Socié G, Mohty M, Sobh M, Bay JO, Morisset S, Labussière-Wallet H, Tabrizi R, Milpied N, Bordigoni P, El-Cheikh J, Blaise D. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. *Exp Hematol*. 2013 Feb;41(2):127-33

280: Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M. Safety and efficacy of rituximab in steroid-refractory chronic GVHD. *Bone Marrow Transplant*. 2013 May;48(5):734-6

281: Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. *Haematologica*. 2013 Feb;98(2):172-8

282: Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Ráčil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol*. 2012 Oct;9(10):579-90

283: Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N, Boiron JM, Fürst S, Castagna L, Chabannon C, Boyer-Chammard A, Milpied N, Labussière-Wallet H, Faucher C, Bardou VJ, Mohty M, Michallet M. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. *Cancer*. 2013 Feb 1;119(3):602-11

284: Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T; MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. *Leukemia*. 2013 Mar;27(3):604-9

285: Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V, Delaunay J, Chevallier P, Guillaume T, Blin N, Ayari S, Clavert A, Mohty M, Dousset C, Milpied N, Harousseau JL, Moreau P, Wuilleme S, Moreau A, Le Gouill S. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? *Transplantation*. 2012 Aug 15;94(3):295-301.

286: Giebel S, Labopin M, Mohty M, Mufti GJ, Niederwieser D, Cornelissen JJ, Janssen JJ, Milpied N, Vindelov L, Petersen E, Arnold R, Bacigalupo A, Blaise D, Craddock C, Nagler A, Frassoni F, Sados-Wojciechowska M, Rocha V. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant.* 2013 Feb;48(2):238-42.

287: Frikeche J, Peric Z, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of HDAC inhibitors on dendritic cell functions. *Exp Hematol.* 2012 Oct;40(10):783-91.

288: Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, Faul C, Guillemin G, Finke J, Huynh A, Schubert J, Kolb HJ, Polge E, Nagler A, Mohty M. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. *Eur J Haematol.* 2012 Sep;89(3):214-9.

289: Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, Socié G, Nagler A, Rocha V, Mohty M. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. *Leukemia.* 2012 Dec;26(12):2462-8

290: Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S, Willemze R, Terriou L, Tichelli A, Mohty M, de Guibert S, Marsh JC, Passweg J, Yves Mary J, Socié G. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. *Haematologica.* 2012 Nov;97(11):1666-73.

291: Xhaard A, Lanternier F, Porcher R, Dannaoui E, Bergeron A, Clement L, Lacroix C, Herbrecht R, Legrand F, Mohty M, Michallet M, Cordonnier C, Malak S, Guyotat D, Couderc LJ, Socié G, Milpied N, Lortholary O, Ribaud P. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). *Clin Microbiol Infect.* 2012 Oct;18(10):E396-400.

292: Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJ, Milpied N, Vindelov L, Petersen E, Gribben J, Bacigalupo A, Malm C, Niederwieser D, Socié GJ, Arnold R, Brown P, Goker H, Rocha V, Mohty M; ALWP-EBMT. Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. *Eur J Haematol.* 2012 Sep;89(3):206-13

293: Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaletteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol.* 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14. Erratum in: *J Clin Oncol.* 2012 Sep 20;30(27):3429. *J Clin Oncol.* 2014 Apr 20;32(12):1285.

- 294: Mohty M. A bit of antithymocyte globulin can take you a long way! Bone Marrow Transplant. 2012 May;47(5):617-8.
- 295: Ruggeri A, Michel G, Dalle JH, Caniglia M, Locatelli F, Campos A, de Heredia CD, Mohty M, Hurtado JM, Bierings M, Bittencourt H, Mauad M, Purtill D, Cunha R, Kabbara N, Gluckman E, Labopin M, Peters C, Rocha V. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia. 2012 Dec;26(12):2455-61.
- 296: Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jun 20;30(18):2211-7.
- 297: Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, de Witte T, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, de Elvira CR, Falkenburg F, Sureda A, Madrigal A; European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012 Jul;47(7):906-23
- 298: Ringdén O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, Greinix HT, Kyrzcz-Krzemien S, Bunjes D, Brinck L, Niederwieser D, Arnold R, Mohty M, Rocha V; Acute Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT). Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med. 2012 Nov;272(5):472-83.
- 299: Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, Sandstedt A, Goker H, Socie G, Rocha V, Mohty M; ALWP of EBMT. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2012 Nov;47(11):1442-7
- 300: Touzeau C, Gagne K, Sébille V, Herry P, Chevallier P, Folléa G, Devys A, Moreau P, Mohty M, Cesbron Gautier A. Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. Hum Immunol. 2012 Jul;73(7):711-4.
- 301: Mohty M, Chevallier P. Azacitidine after allo-SCT: the good without the bad? Blood. 2012 Apr 5;119(14):3199-200. doi: 10.1182/blood-2012-02-406678. PMID: 22493216.
- 302: Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold

R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrzcz-Krzemien S, Rocha V, Mohty M. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2012 Sep;18(9):1422-9.

303: Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. *Ann Oncol*. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.

304: Worel N, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldès C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte RF, Mohty M. European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. *Transfusion*. 2012 Nov;52(11):2395-400.

305: Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, Mohty M, Sureda A, Niederwieser D, Gratwohl A, de Witte T. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2012 Nov;47(11):1459-64

306: Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. *Eur J Haematol*. 2012 Jun;88(6):504-9

307: Michallet M, Sobh M, Milpied N, Bay JO, Fürst S, Harousseau JL, Mohty M, Nicolini FE, Labussière H, Tedone N, Morisset S, Vigouroux S, Baumgart J, Tabrizi R, Blaise D. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. *Ann Hematol*. 2012 Aug;91(8):1289-97.

308: Bossard C, Malard F, Arbez J, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Tiberghien P, Saas P, Mohty M, Gaugler B. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. *Leukemia*. 2012 Jul;26(7):1471-4

309: Ringdén O, Labopin M, Gorin NC, Volin L, Torelli GF, Attal M, Jouet JP, Milpied N, Socié G, Cordonnier C, Michallet M, Atienza AI, Hermine O, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. *Br J Haematol*. 2012 Apr;157(2):220-9.

310: Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V. Impact of FLT3 internal tandem

duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. *J Clin Oncol.* 2012 Mar 1;30(7):735-41

311: Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V; Immunotherapy Subcommittee of Acute Leukemia Working Party. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. *Leukemia.* 2012 Jun;26(6):1211-7.

312: Chevallier P, Robillard N, Charbonnier A, Raffoux E, Maury S, Carras S, Chabrot C, Fohrer C, Bernard M, Blade JS, Etienne A, Talmant P, Delaunay J, Guillaume T, Mohty M, Bene MC, Ifrah N, Dombret H. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. *Blood.* 2012 Mar 15;119(11):2474-7

313: Benrashid M, Moyers K, Mohty M, Savani BN. Vitamin D deficiency, autoimmunity, and graft-versus-host-disease risk: Implication for preventive therapy. *Exp Hematol.* 2012 Apr;40(4):263-7.

314: El-Cheikh J, Crocchiolo R, Boher JM, Fürst S, Stoppa AM, Faucher C, Castagna L, Granata A, Oudin C, De Colella JM, Coso D, Bouabdallah R, Mohty M, Blaise D. Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved? *Leuk Lymphoma.* 2012 Aug;53(8):1630-2.

315: Brissot E, Savani BN, Mohty M. Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. *Semin Hematol.* 2012 Jan;49(1):35-42

316: Touzeau C, Blin N, Clavert A, Roland V, Loirat M, Tessoulin B, Le Gouill S, Planche L, Pennetier M, Mahe B, Mohty M, Malard F, Peterlin P, Dubruille V, Moreau P. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. *Leuk Lymphoma.* 2012 Jul;53(7):1318-20.

317: Frikeche J, Simon T, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of valproic acid on dendritic cells function. *Immunobiology.* 2012 Jul;217(7):704-10..

318: Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. *Leukemia.* 2012 Apr;26(4):582-8

319: Chevallier P, Pigneux A, Robillard N, Ayari S, Guillaume T, Delaunay J, Eveillard M, Dumas PY, Lippert E, Mohty M, Leguay T. Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series. *Leuk Res.* 2012 Mar;36(3):311-5.

320: Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with

relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. *Blood*. 2012 Feb 9;119(6):1599-606.

321: Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A, Rialland F, Le Guill S, Blin N, Gastinne T, Mahé B, Dubruille V, Moreau P, Mohty M. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity. *Bone Marrow Transplant*. 2012 Aug;47(8):1112-7.

322: Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. *Leukemia*. 2012 May;26(5):972-6

323: Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldès C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. *Bone Marrow Transplant*. 2012 Aug;47(8):1046-50.

324: Fabre C, Koscielny S, Mohty M, Fegueux N, Blaise D, Maillard N, Tabrizi R, Michallet M, Socié G, Yakoub-Agha I, Garban F, Uzunov M, François S, Contentin N, Lapusan S, Bourhis JH. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Haematologica*. 2012 Apr;97(4):482-90.

325: Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. *Leukemia*. 2012 Jan;26(1):73-85.

326: Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. *Eur J Haematol*. 2012 Mar;88(3):249-59

327: Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crowley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT). High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. *Biol Blood Marrow Transplant*. 2012 May;18(5):788-93.

328: Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldès C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

329: Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Gerald C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. *Bone Marrow Transplant.* 2012 Jul;47(7):1003-5.

330: Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. *Cancer Control.* 2011 Oct;18(4):237-45. Review.

331: Frikeche J, Clavert A, Delaunay J, Brissot E, Grégoire M, Gaugler B, Mohty M. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. *Exp Hematol.* 2011 Nov;39(11):1056-63.

332: Chabannon C, Calmels B, Habibi S, Mohty M, Imbert AM. [New molecular targets and new clinical practices for hematopoietic stem cell mobilization]. *Bull Cancer.* 2011 Aug;98(8):951-61

333: Le Gouill S, Mohty M, Guillaume T, Gastinne T, Moreau P. Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? *Semin Hematol.* 2011 Jul;48(3):227-39.

334: Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. *Biol Blood Marrow Transplant.* 2012 Feb;18(2):289-94.

335: Faucher C, Le Corroller Soriano AG, Esterni B, Vey N, Stoppa AM, Chabannon C, Mohty M, Michallet M, Bay JO, Genre D, Maraninchi D, Viens P, Moatti JP, Blaise D. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. *Bone Marrow Transplant.* 2012 Apr;47(4):549-55.

336: Chevallier P, Labopin M, Cornelissen J, Socié G, Rocha V, Mohty M; ALWP of EBMT. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. *Haematologica.* 2011 Sep;96(9):1391-4.

337: Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. *Exp Hematol.* 2011 Jul;39(7):723-9.

338: Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. *Biol Blood Marrow Transplant.* 2011 Nov;17(11):1698-703.

339: El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa AM, Bouabdallah R, Coso D, Schiano De Collella JM, Ladaïque P, Gastaut JA, Mohty M, Chabannon C, Blaise D. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. *Hematol Oncol Stem Cell Ther.* 2011;4(1):30-6.

340: Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. *Blood Cancer J.* 2011 Apr;1(4):e16.

341: Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahé B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Coste-Burel M, Imbert-Marcille BM, Mohty M. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation. *Bone Marrow Transplant.* 2012 Feb;47(2):251-7.

342: Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. *Leukemia.* 2011 Jun;25(6):932-8

343: Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, Ehninger G, Steckel NK, Zander AR, Schwerdtfeger R, Buchholz S, Kolb HJ, Volin L, Fauser A, Polge E, Schmid C, Mohty M, Rocha V. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. *Leukemia.* 2011 May;25(5):808-13.

344: Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. *Leukemia.* 2011 Jun;25(6):939-44.

345: Mohty M, Apperley JF. Long-term physiological side effects after allogeneic bone marrow transplantation. *Hematology Am Soc Hematol Educ Program.* 2010;2010:229-36. doi: 10.1182/asheducation-2010.1.229. Review.

346: Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. *Leukemia.* 2011 Jan;25(1):1-6.

347: El Cheikh J, Castagna L, Wang L, Esterni B, Faucher C, Furst S, Duran S, Berger P, Ranque S, Mohty M, Blaise D. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. *Hematol Oncol Stem Cell Ther.* 2010;3(4):167-73.

348: Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, Cahn JY, De

Coninck E, Dhedin N, Bernard M, Rio B, Buzyn A, Huynh A, Bilger K, Bordigoni P, Contentin N, Porcher R, Socié G, Milpied N. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). *Br J Haematol*. 2011 Feb;152(3):331-9.

349: Hantz S, Garnier-Geoffroy F, Mazon MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germe R, Pillet S, Lebranchu Y, Turlure P, Alain S; French CMV Resistance Survey Study Group. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. *J Antimicrob Chemother*. 2010 Dec;65(12):2628-40

350: Castagna L, Fürst S, Marchetti N, El Cheikh J, Faucher C, Mohty M, Bouabdallah R, Vey N, Stoppa AM, Esterni B, Blaise D. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. *Bone Marrow Transplant*. 2011 Jul;46(7):1000-5.

351: Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kroger N, Rocha V. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. *Leukemia*. 2011 Jan;25(1):75-81.

352: Mohty M, Labopin M, Balère ML, Socié G, Milpied N, Tabrizi R, Ifrah N, Hicheri Y, Dhedin N, Michallet M, Buzyn A, Cahn JY, Bourhis JH, Blaise D, Raffoux C, Espérou H, Yakoub-Agha I. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Leukemia*. 2010 Nov;24(11):1867-74.

353: Blaise D, Farnault L, Faucher C, Marchetti N, Fürst S, El Cheikh J, Ladaique P, Vey N, Bouabdallah R, Stoppa AM, Lemarie C, Calmels B, Prebet T, Castagna L, Chabannon C, Mohty M, Esterni B. Reduced-intensity conditioning with Fludarabine, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. *Exp Hematol*. 2010 Dec;38(12):1241-50.

354: Mohty M, Gaugler B. Advances in umbilical cord transplantation: the role of thymoglobulin/ATG in cord blood transplantation. *Best Pract Res Clin Haematol*. 2010 Jun;23(2):275-82.

355: Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. *J Clin Oncol*. 2010 Oct 20;28(30):4621-9.

356: Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J, Tabrizi R, Nagler A, Rocha V; Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. *Blood*. 2010 Nov 25;116(22):4439-43

- 357: Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2011 Jan;17(1):1-17.
- 358: El-Cheikh J, Castagna L, Wang L, Esterni B, Faucher C, Fürst S, Pierre B, Mohty M, Blaise D. Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. *Leuk Lymphoma*. 2010 Sep;51(9):1705-10
- 359: Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. *Blood*. 2010 Nov 18;116(20):4360-7.
- 360: Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. *Leuk Lymphoma*. 2010 Aug;51(8):1502-8.
- 361: Roland V, Bodet-Milin C, Moreau A, Gastinne T, Mahé B, Dubruille V, Maisonneuve H, Juge-Morineau N, Moreau P, Jardel H, Planche L, Mohty M, Moreau P, Harousseau JL, Kraeber-Bodéré F, Le Gouill S. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. *Bone Marrow Transplant*. 2011 Mar;46(3):393-9.
- 362: Strullu M, Corradini N, Audrain M, Orsonneau JL, Bouige D, Thomare P, Vermot-Desroches C, Mansuy A, Legrand A, Rozé JC, Mohty M, Méchinaud F. Silent hypersensitivity to *Escherichia coli* asparaginase in children with acute lymphoblastic leukemia. *Leuk Lymphoma*. 2010 Aug;51(8):1464-72.
- 363: Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. *Eur J Nucl Med Mol Imaging*. 2010 Aug;37(9):1633-42.
- 364: Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. *Biol Blood Marrow Transplant*. 2010 Jul;16(7):871-90
- 365: Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit anti-thymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. *Drugs*. 2010 Apr 16;70(6):691-732.
- 366: Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M.

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. *Haematologica*. 2010 Feb;95(2):311-9.

367: Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2010 Jan;16(1):28-34.

368: Ma X, Wu D, Sun A, Qiu H, Fu Z, Wu X, Chen S, Mohty M. The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. *Am J Hematol*. 2010 Feb;85(2):141-2.

369: Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette-Bodin C, Coste-Burel M, Riolland F, Mohty M, Imbert-Marcille BM. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. *Bone Marrow Transplant*. 2010 Jul;45(7):1204-11

370: Cahu X, Riolland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. *Biol Blood Marrow Transplant*. 2009 Dec;15(12):1531-7.

371: Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, Lode L, Richebourg S, Blanchet O, Vey N, Ifrah N, Milpied N, Blaise D, Harousseau JL, Mohty M. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. *Leukemia*. 2010 Feb;24(2):467-9

372: Prébet T, Ladaique P, Ferrando M, Chabannon C, Faucher C, De Lavallade H, El-Cheikh J, Furst S, Vey N, Stoppa AM, Viens P, Blaise D, Mohty M. Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. *Exp Hematol*. 2010 Jan;38(1):55-60.

373: Mohty M. Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! *Leukemia*. 2009 Oct;23(10):1689-90.

374: Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, François S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillem G, de Revel T, Bay JO, Guilhot F, Milpied N. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Biol Blood Marrow Transplant*. 2010 Jan;16(1):78-85.

375: Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Moreau P, Harousseau JL, Mohty M. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity

preparative regimen and allo-SCT from HLA-matched unrelated donors. *Bone Marrow Transplant.* 2010 Apr;45(4):786-8

376: Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. *Biol Blood Marrow Transplant.* 2009 Sep;15(9):1005-13

377: Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, Finke J, Schwerdtfeger R, Eder M, Bunjes D, Gorin NC, Mohty M, Rocha V. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. *J Clin Oncol.* 2009 Sep 20;27(27):4570-7

378: Chevallier P, Prebet T, Turlure P, Hunault M, Vigouroux S, Harousseau JL, Blaise D, Ifrah N, Milpied N, Mohty M. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2010 Jan;45(1):165-70

379: Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander AR, Blaise D, Mohty M, Kröger N. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. *Bone Marrow Transplant.* 2010 Feb;45(2):349-53.

380: Rocha V, Mohty M, Gluckman E, Rio B; Eurocord; Reduced-Intensity Conditioning Subcommittee of the Acute Leukaemia Working Party; French Society of Bone Marrow Transplantation and Cellular Therapy. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. *Curr Opin Oncol.* 2009 Jun;21 Suppl 1:S31-4.

381: Mohty M, Rocha V, Chevallier P, Harousseau JL, Nagler A. Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later. *Curr Opin Oncol.* 2009 Jun;21 Suppl 1:S1

382: Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. *Immunobiology.* 2010;215(2):113-23.

383: Chevallier P, Labopin M, Nagler A, Ljungman P, Verdonck LF, Volin L, Zander AR, Finke J, Socie G, Cordonnier C, Harousseau JL, Mohty M, Rocha V; Acute Leukemia Working Party of the EBMT. Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. *Bone Marrow Transplant.* 2009 Nov;44(9):589-94.

384: Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Flandrois G, Devys A, Stocco V, Cesbron A, Dehaut F, Moreau P, Harousseau JL, Mohty M. Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors. *Bone Marrow Transplant.* 2009 Nov;44(9):613-5

- 385: Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. *Blood*. 2009 Jul 16;114(3):719-22.
- 386: Mohty M. [Allogeneic hematopoietic stem cell transplantation]. *Rev Prat*. 2008 Dec 15;58(19):2111-22. French.
- 387: Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kögler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V; Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. *Leukemia*. 2009 Mar;23(3):492-500.
- 388: Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, de Lima M, Cairo MS, Fürst S, Rio B, Dalley C, Carreras E, Harousseau JL, Mohty M, Taveira D, Dreger P, Sureda A, Gluckman E, Rocha V. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol*. 2009 Jan 10;27(2):256-63.
- 389: Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. *Br J Haematol*. 2008 Dec;143(5):744-6.
- 390: Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. *Leukemia*. 2009 Apr;23(4):806-7.
- 391: Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL; IFM Group. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. *Blood*. 2008 Nov 1;112(9):3914-5.
- 392: Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. *J Clin Oncol*. 2008 Nov 10;26(32):5192-7.
- 393: Mohty M, Gaugler B. Mechanisms of action of antithymocyte globulin: old dogs with new tricks! *Leuk Lymphoma*. 2008 Sep;49(9):1664-7. doi: 10.1080/10428190802163321. Review. PMID: 18798101.
- 394: Cahu X, Mohty M, Faucher C, Chevalier P, Vey N, El-Cheikh J, Guillaume T, Furst S, Delaunay J, Ayari S, Moreau P, Gastaut JA, Harousseau JL, Blaise D.

Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. *Bone Marrow Transplant*. 2008 Nov;42(10):689-91.

395: El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM, Auran-Schleinitz T, Gastaut JA, Blaise D, Mohty M. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. *Clin Lymphoma Myeloma*. 2008 Jun;8(3):146-52.

396: de Lavallade H, Cassier PA, Bouabdallah R, El-Cheikh J, Faucher C, Fürst S, Coso D, Sainty D, Arnoulet C, Gastaut JA, Chetaille B, Xerri L, Blaise D, Mohty M. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma. *Br J Haematol*. 2008 Sep;142(5):848-50

397: Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, Bordigoni P, Vernant JP, Hunault M, Vigouroux S, Blaise D, Tabrizi R, Buzyn A, Socie G, Michallet M, Volteau C, Harousseau JL. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. *J Clin Oncol*. 2008 Oct 20;26(30):4940-3.

398: Mohty M, de Lavallade H, El-Cheikh J, Ladaïque P, Faucher C, Fürst S, Vey N, Coso D, Stoppa AM, Gastaut JA, Chabannon C, Blaise D. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. *Leukemia*. 2009 Jan;23(1):194-6

399: Mohty M, Szydlo RM, Yong AS, Apperley JF, Goldman JM, Melo JV. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. *Blood*. 2008 Sep 1;112(5):2163-6.

400: de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY, Socié G; French Society of Hematology; French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. *Blood*. 2008 Oct 15;112(8):3099-106.

401: Mami NB, Mohty M, Auran-Schleinitz T, Olive D, Gaugler B. Blood dendritic cells in patients with chronic lymphocytic leukaemia. *Immunobiology*. 2008;213(6):493-8.

402: Mohty M. Systemic lupus erythematosus. *N Engl J Med*. 2008 May 29;358(22):2412-3; author reply 2413.

403: Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M; Société Française de Greffe de Moëlle et de Thérapie Cellulaire. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire. *J Clin Oncol*. 2008 May 10;26(14):2264-71

- 404: Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. *Exp Hematol.* 2008 May;36(5):535-44
- 405: de Lavallade H, El-Cheikh J, Faucher C, Fürst S, Stoppa AM, Coso D, Bouabdallah R, Chabannon C, Gastaut JA, Blaise D, Mohty M. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. *Bone Marrow Transplant.* 2008 Jun;41(11):953-60.
- 406: El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, Faucher C, Sobh M, Revesz D, Hardan I, Fürst S, Blaise D, Mohty M. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. *Haematologica.* 2008 Mar;93(3):455-8
- 407: Mohty M, Marchetti N, El-Cheikh J, Faucher C, Fürst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. *Bone Marrow Transplant.* 2008 May;41(10):909-11.
- 408: Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V; Acute Leukemia Working Party; European Group for Blood and Marrow Transplantation. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. *Haematologica.* 2008 Feb;93(2):303-6.
- 409: Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, Monchecourt F, Mahi L, Ribaud P. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. *Int J Antimicrob Agents.* 2008 Feb;31(2):135-41. Epub 2007 Dec 26.
- 410: Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. *Cytokine Growth Factor Rev.* 2008 Feb;19(1):53-63. Epub 2007 Dec 20. Review.
- 411: Mohty M. Dendritic cells and acute graft-versus-host disease after allogeneic stem cell transplantation. *Leuk Lymphoma.* 2007 Sep;48(9):1696-701. Review. P
- 412: Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, Michallet M, Doyen C, Leyvraz S, Mohty M, Wetterwald M, Mathiot C, Caillot D, Berthou C, Benboubker L, Garderet L, Chateix C, Traullé C, Fuzibet JG, Jaubert J, Lamy T, Casassus P, Dib M, Kolb B, Dorvaux V, Grosbois B, Yakoub-Agha I, Harousseau JL, Avet-Loiseau H; SAKK; IFM Group. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. *Leukemia.* 2007 Sep;21(9):2020-4. Epub 2007 Jul 12. .

- 413: Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. *Haematologica*. 2007 Jul;92(7):1004-6.
- 414: Meniane JC, El-Cheikh J, Faucher C, Fürst S, Bouabdallah R, Blaise D, Mohty M. Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2007 Jul;40(2):175-7. Epub 2007 May 14.
- 415: Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2007 Apr;92(4):533-41. Review.
- 416: Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. *Leukemia*. 2007 Jul;21(7):1387-94. Epub 2007 Apr 5. Review.
- 417: Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. *Blood*. 2007 Jul 1;110(1):380-3. Epub 2007 Mar 14.
- 418: El-Cheikh J, Faucher C, Fürst S, Duran S, Berger P, Vey N, Stoppa AM, Bouabdallah R, Gastaut JA, Viens P, Blaise D, Mohty M. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2007 Mar;39(5):301-6. Epub 2007 Jan 29.
- 419: Mohty M, Nagler A, Killmann NM. Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? *Leukemia*. 2006 Oct;20(10):1653-4.
- 420: de Lavallade H, Mohty M, El-Cheikh J, Cassier PA, Faucher C, Fürst S, Vey N, Stoppa AM, Sainty D, Arnoulet C, Xerri L, Gastaut JA, Blaise D, Bouabdallah R. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. *Br J Haematol*. 2006 Nov;135(3):408-10. Epub 2006 Sep 15. .
- 421: de Lavallade H, Mohty M, Faucher C, Fürst S, El-Cheikh J, Blaise D. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. *Haematologica*. 2006 Oct;91(10):1438-40. Epub 2006 Sep 7.
- 422: de Lavallade H, Faucher C, Fürst S, El-Cheikh J, Vey N, Coso D, Bouabdallah R, Stoppa AM, Gastaut JA, Blaise D, Mohty M. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. *Bone Marrow Transplant*. 2006 Apr;37(7):709-10.
- 423: Mohty M. CD25 expression on donor CD8+ T cells and graft-versus-host disease. *Haematologica*. 2005 Oct;90(10):1302A.

424: Blaise D, Mohty M, Faucher C, Olive D, Chabannon C. Current update on reduced intensity regimens for allogeneic stem cell transplantation. *Hematology*. 2005;10 Suppl 1:64-5. Review.

425: Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. *Cancer*. 2005 Nov 1;104(9):1931-8.

426: Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Viens P, Maraninchi D, Bardoux VJ, Esterni B, Blaise D. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2005 Nov;36(10):901-6.

427: Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM, Viret F, Gravis G, Olive D, Gaugler B. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. *Blood*. 2005 Dec 15;106(13):4407-11. Epub 2005 Sep 1.

428: Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. *Trends Mol Med*. 2005 Sep;11(9):397-402.

429: Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D, Stoppa AM, Gastaut JA, Blaise D. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. *Leukemia*. 2005 Jun;19(6):916-20. PMID: 15843817.

430: Mohty M, Faucher C, Blaise D. Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. *Leukemia*. 2005 Apr;19(4):500-3.

431: Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA. Single-agent thalidomide induces response in T-cell lymphoma. *Eur J Haematol*. 2005 Feb;74(2):169-71.

432: Mohty M, Faucher C, Blaise D. [Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]. *Rev Med Interne*. 2005 Jan;26(1):33-40. Review. French.

433: Mohty M, Bagattini S, Chabannon C, Faucher C, Bardoux VJ, Bilger K, Vey N, Gaugler B, Stoppa AM, Coso D, Ladaique P, Olive D, Viens P, Blaise D. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. *Exp Hematol*. 2004 Nov;32(11):1097-102.

434: Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N, Rio B, Vernant JP, Sotto JJ, Cahn JY, Blaise D, Jouet JP, Facon T, Yakoub-Agha I. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple

myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2005 Jan;35(2):165-9.

435: Mohty M, Blaise D, Faucher C, Bardou VJ, Gastaut JA, Viens P, Olive D, Gaugler B. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia. 2005 Jan;19(1):1-6.

436: Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, Stoppa AM, Gastaut JA. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol. 2004 Dec;73(6):402-6. Review.

437: Véran J, Mohty M, Gaugler B, Chiavaroli C, Olive D. OM-197-MP-AC adjuvant properties: the in vitro maturation of normal and leukemic dendritic cells in a serum-free culture model. Immunobiology. 2004;209(1-2):67-77.

438: Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM, Gravis G, Coso D, Viens P, Gastaut JA, Blaise D. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2004 Sep;34(6):527-30.

439: Mohty M, Olive D, Gaugler B. Plasmacytoid DCs and cancer: a new role for an enigmatic cell. Trends Immunol. 2004 Aug;25(8):397-8; author reply 398-9.

440: Mami NB, Mohty M, Chambost H, Gaugler B, Olive D. Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br J Haematol. 2004 Jul;126(1):77-80.

441: Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2004 Jul;34(1):77-84.

442: Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D, Arnoulet C, Chabannon C, Vey N, Camerlo J, Bouabdallah R, Maraninchi D, Bardou VJ, Blaise D. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion. 2004 Apr;44(4):501-8.

443: Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant. 2004 Apr;33(8):839-46.

444: Vialle-Castellano A, Gaugler B, Mohty M, Isnardon D, van Baren N, Olive D. Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia. 2004 Mar;18(3):426-33.

445: Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D, Isnardon D, Olive D, Gaugler B. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood. 2004 Jun 15;103(12):4666-8. Epub 2004 Jan 8.

446: Mohty M, Gaugler B, Calmels B, Blaise D, Vey N, Chabannon C, Olive D.

[Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]. *Bull Cancer*. 2003 Aug-Sep;90(8-9):751-7. Review. French.

447: Ivanov V, Faucher C, Bilger K, Vey N, Sainty D, Calmels B, Chabannon C, Lafage-Pochitaloff M, Mozziconacci MJ, Mohty M, Chrestian MA, Blaise D. Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL. *Bone Marrow Transplant*. 2003 Nov;32(9):961-3.

448: Faucher C, Mohty M, Vey N, Gaugler B, Bilger K, Mozziconacci MJ, Stoppa AM, Coso D, Ladaïque P, Chabannon C, Reviron D, Maraninchi D, Gastaut JA, Olive D, Blaise D. Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. *Exp Hematol*. 2003 Oct;31(10):873-80.

449: Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. *J Immunol*. 2003 Oct 1;171(7):3385-93.

450: Mohty M, Gaugler B. Dendritic cells: interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3-8 March 2003. *Leukemia*. 2003 Sep;17(9):1753-8.

451: Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B, Cahn JY, Gratecos N, Sotto JJ, François S, Fleury J, Mohty M, Chabannon C, Bilger K, Gravis G, Viret F, Braud AC, Bardou VJ, Maraninchi D, Viens P. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. *Blood*. 2004 Jan 15;103(2):435-41. Epub 2003 Aug 28.

452: Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. *Leukemia*. 2003 Nov;17(11):2168-77.

453: Mohty M, Morbelli S, Isnardon D, Sainty D, Arnoulet C, Gaugler B, Olive D. All-trans retinoic acid skews monocyte differentiation into interleukin-12-secreting dendritic-like cells. *Br J Haematol*. 2003 Sep;122(5):829-36.

454: Mohty M, Olive D. [Can one separate GVH and GVT after allogeneic hematopoietic stem cell transplantation?]. *Med Sci (Paris)*. 2003 May;19(5):540-1. French.

455: Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Sadoun A, Ifrah N, Guyotat D, Faucher C, Fegueux N, Reiffers J, Maraninchi D, Blaise D. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. *Leukemia*. 2003 May;17(5):869-75.

456: Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Chabannon C, Viens P, Maraninchi D, Blaise D. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. *Blood*. 2003 Jul 15;102(2):470-6. Epub 2003 Mar 20.

457: Mohty M, Gaugler B, Olive D. Generation of leukemic dendritic cells from

patients with acute myeloid leukemia. *Methods Mol Biol.* 2003;215:463-71.

458: Mohty M, Stoppa AM, Blaise D, Isnardon D, Gastaut JA, Olive D, Gaugler B. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. *J Leukoc Biol.* 2002 Nov;72(5):939-45.

459: Mohty M, Isnardon D, Blaise D, Mozziconacci MJ, Lafage-Pochitaloff M, Brière F, Gastaut JA, Olive D, Gaugler B. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. *Leukemia.* 2002 Nov;16(11):2267-74.

460: Mohty M, Olive D, Gaugler B. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. *Leukemia.* 2002 Nov;16(11):2197-204. Review.

461: Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Blaise D; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. *Blood.* 2002 Nov 1;100(9):3128-34.

462: Mohty M, Isnardon D, Vey N, Brière F, Blaise D, Olive D, Gaugler B. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38- primitive haematopoietic progenitors. *Br J Haematol.* 2002 Oct;119(1):115-8.

463: Mohty M, Faucher C, Vey N, Chabannon C, Sainty D, Arnoulet C, Gaugler B, Gastaut JA, Maraninchi D, Olive D, Blaise D. Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. *Leukemia.* 2002 Oct;16(10):2129-33.

464: Mohty M, Gaugler B, Faucher C, Sainty D, Lafage-Pochitaloff M, Vey N, Bouabdallah R, Arnoulet C, Gastaut JA, Viret F, Wolfers J, Maraninchi D, Blaise D, Olive D. Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. *Hematology.* 2002 Jun;7(3):157-64.

465: Mohty M, Isnardon D, Charbonnier A, Lafage-Pochitaloff M, Merlin M, Sainty D, Olive D, Gaugler B. Generation of potent T(h)1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells. *Int Immunol.* 2002 Jul;14(7):741-50.

466: Mohty M, Faucher C, Chabannon C, Vey N, Stoppa AM, Ladaïque P, Novakovitch G, Olivero S, Bouabdallah R, Gastaut JA, Maraninchi D, Blaise D. CD34(+) immunoselected cells for poor graft function following allogeneic BMT. *Cytotherapy.* 2000;2(5):367-70.

467: Mohty M, Faucher C, Gaugler B, Vey N, Sainty D, Arnoulet C, Mozziconacci MJ, Isnardon D, Gastaut JA, Maraninchi D, Olive D, Blaise D. Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report. *Bone Marrow Transplant.* 2001 Dec;28(12):1157-60.

468: Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Brière F, de Lamballeri XN, Isnardon D, Sainty D, Olive D, Gaugler B. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. *Blood.* 2001 Dec 15;98(13):3750-6.

469: Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF. Reduced intensity

conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. *Bone Marrow Transplant*. 2001 Aug;28(4):335-9.

470: Mohty M, Albat B, Fegueux N, Rossi JF. Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis. *Leuk Lymphoma*. 2001 Mar;41(1-2):221-3.

471: Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Chabannon C, Bouabdallah R, Ladaïque P, Collet L, Zandotti C, Maraninchi D, Blaise D. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. *Bone Marrow Transplant*. 2000 Aug;26(3):251-5.

472: Mohty M, Peyriere H, Guinet C, Hillaire-Buys D, Blayac JP, Rossi JF. Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. *Leuk Lymphoma*. 2000 Apr;37(3-4):441-3.